M&A deals, company strategies, pipeline updates and more
Follow our coverage of the 2019 J.P. Morgan Healthcare Conference in San Francisco
Fresh from reporting clinical data at ASH, Immunochina has raised $20 million to speed up its CAR-T development programs.
VOS failed to best the tolerability of Allergan's Restasis but delivered superior efficacy, suggesting it may have an unexpected edge over its rival.
Gamida Cell brought on a subsidiary of the National Marrow Donor Program to support a phase 3 study of its blood cancer cell therapy alternative.
Wren Therapeutics will use the series A round to advance its research into drugs to treat protein-misfolding diseases such as Alzheimer’s.
A Fred Hutch team has figured out how to kill dormant breast cancer cells using compounds that disrupt a protective signaling system.
Redx was hit hard last year when it was forced to suspend a phase 1/2a trial of its porcupine inhibitor for solid tumors, but it’s now been given the OK to…
Samantha Paston’s appointment is part of a broader effort by Scancell to add experience as it steps up its immunotherapy development activities.
The fund funneled around $16 million (€14 million) into the startups to support research into antibiotics and prophylactic vaccines.
A connection between TDP-43, which has been implicated in ALS, and another gene could yield new approaches to treating the disease.
CMO Sean Bohen and I-O head David Berman are leaving AstraZeneca, while Roche's Omar Khwaja and Pearl Huang land at new biotechs.
